Search
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalMitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading
Molibresib
go.drugbank.com/drugs/DB16239InvestigationalMolibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects
Nanoparticle Epirubicin
go.drugbank.com/drugs/DB16248InvestigationalIt is a novel [epirubicin] drug-conjugated polymeric micelle.
Nevanimibe
go.drugbank.com/drugs/DB16254InvestigationalNevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigationalNipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases.
Olacaftor
go.drugbank.com/drugs/DB16262InvestigationalOlacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Olaparib-bodipy FL
go.drugbank.com/drugs/DB16263InvestigationalOlaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).
Olenasufligene relduparvovec
go.drugbank.com/drugs/DB16264InvestigationalIt is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.[L46671]
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [A254726,A254731] Olutasidenib inhibits the mutated IDH1 specifically, and provides a therapeutic benefit in IDH1-mutated cancers.
Ontuxizumab
go.drugbank.com/drugs/DB16270InvestigationalOntuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1).